Review



matrix metallopeptidase 9  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    R&D Systems matrix metallopeptidase 9
    Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and <t>MMP9</t> determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
    Matrix Metallopeptidase 9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 142 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metallopeptidase+9/Human+MMP-9+DuoSet+ELISA/pmc13054578-81-14-19
    Average 95 stars, based on 142 article reviews
    matrix metallopeptidase 9 - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis"

    Article Title: The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis

    Journal: Military Medical Research

    doi: 10.1016/j.mmr.2026.100010

    Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and MMP9 determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
    Figure Legend Snippet: Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and MMP9 determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.

    Techniques Used: Concentration Assay, Incubation, Ex Vivo, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Control, Bacteria

    Diagnostic performance for the detection of bacteremia, analyzing the neutrophil phenotype by determining the median fluorescence intensity (MFI) and the cellular response capacity (CRC) in comparison with traditional markers of humoral inflammation (IL-6, IL-8, MMP9). a Comparison of receiver operating characteristic (ROC) at 10,000 CFU/ml Escherichia coli ( E. coli ) with the respective 95% confidence interval (CI) and P -value, and half-maximal effective concentration (EC 50 ) as a function of the E. coli concentration. b Detailed comparison of the EC 50 as a function of the E. coli concentration. c Exemplary comparison of EC 50 curve fit after normalization as indicated by EC 50 (%) on the respective Y-axis to BuC=100% and 50 000 CFU/ml E. coli =0% for the humoral marker IL-6 (the IL-6 values were multiplied by −1 before EC 50 calculation to facilitate comparability with the CRC) and the change in neutrophil phenotype represented by CD11b CRC. BuC indicates buffer control after 60 min incubation; numbers on the X-axis of c indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, evaluating the EC 50 of IL-8, MMP9, the MFI, and CRC of CD10, CD11b, and CD62L in comparison to the EC 50 of IL-6. P -values are indicated above the respective data points. ⁎ P <0.05. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
    Figure Legend Snippet: Diagnostic performance for the detection of bacteremia, analyzing the neutrophil phenotype by determining the median fluorescence intensity (MFI) and the cellular response capacity (CRC) in comparison with traditional markers of humoral inflammation (IL-6, IL-8, MMP9). a Comparison of receiver operating characteristic (ROC) at 10,000 CFU/ml Escherichia coli ( E. coli ) with the respective 95% confidence interval (CI) and P -value, and half-maximal effective concentration (EC 50 ) as a function of the E. coli concentration. b Detailed comparison of the EC 50 as a function of the E. coli concentration. c Exemplary comparison of EC 50 curve fit after normalization as indicated by EC 50 (%) on the respective Y-axis to BuC=100% and 50 000 CFU/ml E. coli =0% for the humoral marker IL-6 (the IL-6 values were multiplied by −1 before EC 50 calculation to facilitate comparability with the CRC) and the change in neutrophil phenotype represented by CD11b CRC. BuC indicates buffer control after 60 min incubation; numbers on the X-axis of c indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, evaluating the EC 50 of IL-8, MMP9, the MFI, and CRC of CD10, CD11b, and CD62L in comparison to the EC 50 of IL-6. P -values are indicated above the respective data points. ⁎ P <0.05. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.

    Techniques Used: Diagnostic Assay, Fluorescence, Comparison, Concentration Assay, Marker, Control, Incubation, Bacteria

    Clinical specifications and parameters over all time points of the sepsis cohort. a Suspected infection cause of sepsis. b Distribution of the individual score points of the Sequential Organ Failure Assessment (SOFA) score. c Total SOFA score. d-h Traditional and humoral markers of inflammation: leukocytes and neutrophil-lymphocyte ratio ( d ), C-reactive protein (CRP) and procalcitonin (PCT) ( e ), interleukin-6 (IL-6) and interleukin-8 (IL-8) ( f ), serum amyloid A (SAA) and calprotectin ( g ), matrix metallopeptidase 9 (MMP9) and myeloperoxidase (MPO) ( h ). Values are shown as median and interquartile range. n =14. CNS. Central nervous system; HV. Healthy volunteers.
    Figure Legend Snippet: Clinical specifications and parameters over all time points of the sepsis cohort. a Suspected infection cause of sepsis. b Distribution of the individual score points of the Sequential Organ Failure Assessment (SOFA) score. c Total SOFA score. d-h Traditional and humoral markers of inflammation: leukocytes and neutrophil-lymphocyte ratio ( d ), C-reactive protein (CRP) and procalcitonin (PCT) ( e ), interleukin-6 (IL-6) and interleukin-8 (IL-8) ( f ), serum amyloid A (SAA) and calprotectin ( g ), matrix metallopeptidase 9 (MMP9) and myeloperoxidase (MPO) ( h ). Values are shown as median and interquartile range. n =14. CNS. Central nervous system; HV. Healthy volunteers.

    Techniques Used: Infection

    Related Articles

    Clinical Proteomics:

    Article Title: Platelet‐Activating Factor Promotes Neutrophil Activation and Platelet–Neutrophil Complex Formation
    Article Snippet: .. Measurement of plasma levels of matrix metallopeptidase 9 (MMP9, #DY911, R&D Systems, Minneapolis, USA), interleukin‐6 (IL‐6, #555220, BD Bioscienes), IL‐8 (#DY208, R&D Systems), and neutrophil elastase (NE, #DY9167‐05, R&D Systems) was conducted using citrate‐anticoagulated plasma and by standard enzyme‐linked immunosorbent assay (ELISA) as indicated by the manufacturer. ..

    Article Title: Platelet-Activating Factor Promotes Neutrophil Activation and Platelet-Neutrophil Complex Formation.
    Article Snippet: .. Measurement of plasma levels of matrix metallopeptidase 9 (MMP9, #DY911, R&D Systems, Minneapolis, USA), interleukin- 6 (IL- 6, #555220, BD Bioscienes), IL- 8 (#DY208, R&D Systems), and neutrophil elastase (NE, #DY9167- 05, R&D Systems) was conducted using citrate- anticoagulated plasma and by standard enzyme- linked immunosorbent assay (ELISA) as indicated by the manufacturer. ..

    Article Title: The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis
    Article Snippet: .. For the samples of the ex vivo whole blood model, the plasma concentrations of matrix metallopeptidase 9 (MMP9, #DY911, R&D Systems, Minneapolis, USA), IL-6 (#555220, BD Biosciences, San Jose, USA), and IL-8 (#DY208, R&D Systems) were measured in citrate-anticoagulated plasma using enzyme-linked immunosorbent assay according to the respective manufacturer’s instructions. .. For all samples from the patient cohorts, myeloperoxidase (MPO), MMP9, serum amyloid A (SAA), and calprotectin (also known as MRP8-14) were quantified using a LEGENDplex Human Vascular Inflammation Panel 1-S/P (#740809, Biolegend, San Diego, USA) in accordance with the manufacturer’s instructions.

    Enzyme-linked Immunosorbent Assay:

    Article Title: Platelet‐Activating Factor Promotes Neutrophil Activation and Platelet–Neutrophil Complex Formation
    Article Snippet: .. Measurement of plasma levels of matrix metallopeptidase 9 (MMP9, #DY911, R&D Systems, Minneapolis, USA), interleukin‐6 (IL‐6, #555220, BD Bioscienes), IL‐8 (#DY208, R&D Systems), and neutrophil elastase (NE, #DY9167‐05, R&D Systems) was conducted using citrate‐anticoagulated plasma and by standard enzyme‐linked immunosorbent assay (ELISA) as indicated by the manufacturer. ..

    Article Title: Platelet-Activating Factor Promotes Neutrophil Activation and Platelet-Neutrophil Complex Formation.
    Article Snippet: .. Measurement of plasma levels of matrix metallopeptidase 9 (MMP9, #DY911, R&D Systems, Minneapolis, USA), interleukin- 6 (IL- 6, #555220, BD Bioscienes), IL- 8 (#DY208, R&D Systems), and neutrophil elastase (NE, #DY9167- 05, R&D Systems) was conducted using citrate- anticoagulated plasma and by standard enzyme- linked immunosorbent assay (ELISA) as indicated by the manufacturer. ..

    Article Title: Pre-Administration of PLX-R18 Cells Protects Mice from Radiation-Induced Hematopoietic Failure and Lethality.
    Article Snippet: .. ELISA to Quantify Radiation Injury and Endothelial Biomarkers from Serum Mouse Erythropoietin (EPO), Serum Amyloid (SAA), Flt3 ligand (Flt3L), E-Selectin, sP-Selectin and matrix metallopeptidase 9 (MMP-9) (R&D Systems, Minneapolis, MN, USA) and Mouse Procalcitonin (PCT) ELISA kit (My Biosource, San Diego, CA, USA) were used to quantify from serum, following vendor protocols. ..

    Article Title: Increased Monocyte-Derived CD11b + Macrophage Subpopulations Following Cigarette Smoke Exposure Are Associated With Impaired Bleomycin-Induced Tissue Remodelling
    Article Snippet: .. Matrix metallopeptidase 9 (MMP9; #DY6718 R&D Systems, ON, Canada) ELISA, and CyQUANTTM lactose dehydrogenase (LDH; #C20301 ThermoFisher Scientific, ON, Canada) cytotoxicity assay, and soluble collagen assessed using sircol assay (SircolTM Soluble Collagen Assay #CLRS1000, Biocolor, UK) were performed on cell culture supernatant. .. Lung (right superior lobe) homogenate was processed using Bullet Blender 24 Gold (Next Advance, Troy NY USA) either in PBS or RLT lysis buffer (Qiagen, Valencia, CA, USA) for protein and RNA analysis respectively.

    Article Title: LYVE-1 identifies asthma and drives PDGF-BB-induced proliferation, migration, and oxidative stress in airway smooth muscle cells via the PI3K/Akt pathway
    Article Snippet: .. An enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of interleukin-4 (IL-4; D4050, R&D Systems), interleukin-5 (IL-5; D5000B, R&D Systems), interleukin-13 (IL-13; D1300B, R&D Systems), vascular endothelial growth factor A (VEGF-A; SEKH-0052, Solarbio), stromal cell-derived factor 1 alpha (SDF-1α; ml038196, Shanghai Enzyme-linked Biotechnology), transforming growth factor beta 1 (TGF-β1; DY240, R&D Systems), matrix metallopeptidase 9 (MMP-9; DMP900, R&D Systems), hyaluronan (DHYAL0, R&D Systems), and soluble lymphatic vessel endothelial hyaluronan receptor 1 (sLYVE1; DY2089, R&D). ..

    Membrane:

    Article Title: Ulmus macrocarpa Hance trunk bark extracts inhibit RANKL-induced osteoclast differentiation and prevent ovariectomy-induced osteoporosis in mice.
    Article Snippet: Ethnopharmacological relevance: Ulmus macrocarpa Hance (UmH) bark has been traditionally utilized for medicinal purposes.. The bark extract of this plant has diverse health benefits, and its potential role in enhancing bone health is of distinct interest, particularly when considering the substantial health and economic implications of bone-related pathologies, such as osteoporosis.. Despite the compelling theoretical implications of UmH bark in fortifying bone health, no definitive evidence at the in vivo level is currently available, thus highlighting the innovative and as-yet-unexplored potential of this field of study.

    Recombinant:

    Article Title: Demonstration of elevated levels of active cathepsin S in dextran sulfate sodium colitis using a new activatable probe.
    Article Snippet: Background Proteases play a major role in inflammatory diseases of the gastrointestinal tract.. Activatable probes are a major technological advance, enabling sensitive detection of active proteases in tissue samples.. Our aim was to synthesize an activatable probe for cathepsin S and validate its use in a mouse model of colitis.

    Ex Vivo:

    Article Title: The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis
    Article Snippet: .. For the samples of the ex vivo whole blood model, the plasma concentrations of matrix metallopeptidase 9 (MMP9, #DY911, R&D Systems, Minneapolis, USA), IL-6 (#555220, BD Biosciences, San Jose, USA), and IL-8 (#DY208, R&D Systems) were measured in citrate-anticoagulated plasma using enzyme-linked immunosorbent assay according to the respective manufacturer’s instructions. .. For all samples from the patient cohorts, myeloperoxidase (MPO), MMP9, serum amyloid A (SAA), and calprotectin (also known as MRP8-14) were quantified using a LEGENDplex Human Vascular Inflammation Panel 1-S/P (#740809, Biolegend, San Diego, USA) in accordance with the manufacturer’s instructions.

    Cytotoxicity Assay:

    Article Title: Increased Monocyte-Derived CD11b + Macrophage Subpopulations Following Cigarette Smoke Exposure Are Associated With Impaired Bleomycin-Induced Tissue Remodelling
    Article Snippet: .. Matrix metallopeptidase 9 (MMP9; #DY6718 R&D Systems, ON, Canada) ELISA, and CyQUANTTM lactose dehydrogenase (LDH; #C20301 ThermoFisher Scientific, ON, Canada) cytotoxicity assay, and soluble collagen assessed using sircol assay (SircolTM Soluble Collagen Assay #CLRS1000, Biocolor, UK) were performed on cell culture supernatant. .. Lung (right superior lobe) homogenate was processed using Bullet Blender 24 Gold (Next Advance, Troy NY USA) either in PBS or RLT lysis buffer (Qiagen, Valencia, CA, USA) for protein and RNA analysis respectively.

    Collagen Assay:

    Article Title: Increased Monocyte-Derived CD11b + Macrophage Subpopulations Following Cigarette Smoke Exposure Are Associated With Impaired Bleomycin-Induced Tissue Remodelling
    Article Snippet: .. Matrix metallopeptidase 9 (MMP9; #DY6718 R&D Systems, ON, Canada) ELISA, and CyQUANTTM lactose dehydrogenase (LDH; #C20301 ThermoFisher Scientific, ON, Canada) cytotoxicity assay, and soluble collagen assessed using sircol assay (SircolTM Soluble Collagen Assay #CLRS1000, Biocolor, UK) were performed on cell culture supernatant. .. Lung (right superior lobe) homogenate was processed using Bullet Blender 24 Gold (Next Advance, Troy NY USA) either in PBS or RLT lysis buffer (Qiagen, Valencia, CA, USA) for protein and RNA analysis respectively.

    Cell Culture:

    Article Title: Increased Monocyte-Derived CD11b + Macrophage Subpopulations Following Cigarette Smoke Exposure Are Associated With Impaired Bleomycin-Induced Tissue Remodelling
    Article Snippet: .. Matrix metallopeptidase 9 (MMP9; #DY6718 R&D Systems, ON, Canada) ELISA, and CyQUANTTM lactose dehydrogenase (LDH; #C20301 ThermoFisher Scientific, ON, Canada) cytotoxicity assay, and soluble collagen assessed using sircol assay (SircolTM Soluble Collagen Assay #CLRS1000, Biocolor, UK) were performed on cell culture supernatant. .. Lung (right superior lobe) homogenate was processed using Bullet Blender 24 Gold (Next Advance, Troy NY USA) either in PBS or RLT lysis buffer (Qiagen, Valencia, CA, USA) for protein and RNA analysis respectively.



    Similar Products

    95
    R&D Systems matrix metallopeptidase 9
    Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and <t>MMP9</t> determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
    Matrix Metallopeptidase 9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metallopeptidase+9/Human+MMP-9+DuoSet+ELISA/pmc13054578-81-14-19
    Average 95 stars, based on 1 article reviews
    matrix metallopeptidase 9 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    96
    Proteintech anti matrix metallopeptidase 9 mmp9
    Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and <t>MMP9</t> determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
    Anti Matrix Metallopeptidase 9 Mmp9, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metallopeptidase+9/MMP9+(N-terminal)+Polyclonal+antibody/pmc13049008-113-29-35
    Average 96 stars, based on 1 article reviews
    anti matrix metallopeptidase 9 mmp9 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology anti matrix metallopeptidase 9 mmp9
    Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and <t>MMP9</t> determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
    Anti Matrix Metallopeptidase 9 Mmp9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metallopeptidase+9/NFATc1+Antibody/pm41813908-121-29-39
    Average 96 stars, based on 1 article reviews
    anti matrix metallopeptidase 9 mmp9 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Proteintech matrix metallopeptidase 9
    Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and <t>MMP9</t> determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
    Matrix Metallopeptidase 9, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metallopeptidase+9/MMP9+(N-terminal)+Polyclonal+antibody/pm41577835-113-38-44
    Average 96 stars, based on 1 article reviews
    matrix metallopeptidase 9 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    97
    Santa Cruz Biotechnology matrix metallopeptidase 9
    Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and <t>MMP9</t> determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
    Matrix Metallopeptidase 9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metallopeptidase+9/MMP-9+Antibody/pm41289876-116-57-65
    Average 97 stars, based on 1 article reviews
    matrix metallopeptidase 9 - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    Image Search Results


    Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and MMP9 determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.

    Journal: Military Medical Research

    Article Title: The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis

    doi: 10.1016/j.mmr.2026.100010

    Figure Lengend Snippet: Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and MMP9 determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.

    Article Snippet: For the samples of the ex vivo whole blood model, the plasma concentrations of matrix metallopeptidase 9 (MMP9, #DY911, R&D Systems, Minneapolis, USA), IL-6 (#555220, BD Biosciences, San Jose, USA), and IL-8 (#DY208, R&D Systems) were measured in citrate-anticoagulated plasma using enzyme-linked immunosorbent assay according to the respective manufacturer’s instructions.

    Techniques: Concentration Assay, Incubation, Ex Vivo, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Control, Bacteria

    Diagnostic performance for the detection of bacteremia, analyzing the neutrophil phenotype by determining the median fluorescence intensity (MFI) and the cellular response capacity (CRC) in comparison with traditional markers of humoral inflammation (IL-6, IL-8, MMP9). a Comparison of receiver operating characteristic (ROC) at 10,000 CFU/ml Escherichia coli ( E. coli ) with the respective 95% confidence interval (CI) and P -value, and half-maximal effective concentration (EC 50 ) as a function of the E. coli concentration. b Detailed comparison of the EC 50 as a function of the E. coli concentration. c Exemplary comparison of EC 50 curve fit after normalization as indicated by EC 50 (%) on the respective Y-axis to BuC=100% and 50 000 CFU/ml E. coli =0% for the humoral marker IL-6 (the IL-6 values were multiplied by −1 before EC 50 calculation to facilitate comparability with the CRC) and the change in neutrophil phenotype represented by CD11b CRC. BuC indicates buffer control after 60 min incubation; numbers on the X-axis of c indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, evaluating the EC 50 of IL-8, MMP9, the MFI, and CRC of CD10, CD11b, and CD62L in comparison to the EC 50 of IL-6. P -values are indicated above the respective data points. ⁎ P <0.05. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.

    Journal: Military Medical Research

    Article Title: The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis

    doi: 10.1016/j.mmr.2026.100010

    Figure Lengend Snippet: Diagnostic performance for the detection of bacteremia, analyzing the neutrophil phenotype by determining the median fluorescence intensity (MFI) and the cellular response capacity (CRC) in comparison with traditional markers of humoral inflammation (IL-6, IL-8, MMP9). a Comparison of receiver operating characteristic (ROC) at 10,000 CFU/ml Escherichia coli ( E. coli ) with the respective 95% confidence interval (CI) and P -value, and half-maximal effective concentration (EC 50 ) as a function of the E. coli concentration. b Detailed comparison of the EC 50 as a function of the E. coli concentration. c Exemplary comparison of EC 50 curve fit after normalization as indicated by EC 50 (%) on the respective Y-axis to BuC=100% and 50 000 CFU/ml E. coli =0% for the humoral marker IL-6 (the IL-6 values were multiplied by −1 before EC 50 calculation to facilitate comparability with the CRC) and the change in neutrophil phenotype represented by CD11b CRC. BuC indicates buffer control after 60 min incubation; numbers on the X-axis of c indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, evaluating the EC 50 of IL-8, MMP9, the MFI, and CRC of CD10, CD11b, and CD62L in comparison to the EC 50 of IL-6. P -values are indicated above the respective data points. ⁎ P <0.05. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.

    Article Snippet: For the samples of the ex vivo whole blood model, the plasma concentrations of matrix metallopeptidase 9 (MMP9, #DY911, R&D Systems, Minneapolis, USA), IL-6 (#555220, BD Biosciences, San Jose, USA), and IL-8 (#DY208, R&D Systems) were measured in citrate-anticoagulated plasma using enzyme-linked immunosorbent assay according to the respective manufacturer’s instructions.

    Techniques: Diagnostic Assay, Fluorescence, Comparison, Concentration Assay, Marker, Control, Incubation, Bacteria

    Clinical specifications and parameters over all time points of the sepsis cohort. a Suspected infection cause of sepsis. b Distribution of the individual score points of the Sequential Organ Failure Assessment (SOFA) score. c Total SOFA score. d-h Traditional and humoral markers of inflammation: leukocytes and neutrophil-lymphocyte ratio ( d ), C-reactive protein (CRP) and procalcitonin (PCT) ( e ), interleukin-6 (IL-6) and interleukin-8 (IL-8) ( f ), serum amyloid A (SAA) and calprotectin ( g ), matrix metallopeptidase 9 (MMP9) and myeloperoxidase (MPO) ( h ). Values are shown as median and interquartile range. n =14. CNS. Central nervous system; HV. Healthy volunteers.

    Journal: Military Medical Research

    Article Title: The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis

    doi: 10.1016/j.mmr.2026.100010

    Figure Lengend Snippet: Clinical specifications and parameters over all time points of the sepsis cohort. a Suspected infection cause of sepsis. b Distribution of the individual score points of the Sequential Organ Failure Assessment (SOFA) score. c Total SOFA score. d-h Traditional and humoral markers of inflammation: leukocytes and neutrophil-lymphocyte ratio ( d ), C-reactive protein (CRP) and procalcitonin (PCT) ( e ), interleukin-6 (IL-6) and interleukin-8 (IL-8) ( f ), serum amyloid A (SAA) and calprotectin ( g ), matrix metallopeptidase 9 (MMP9) and myeloperoxidase (MPO) ( h ). Values are shown as median and interquartile range. n =14. CNS. Central nervous system; HV. Healthy volunteers.

    Article Snippet: For the samples of the ex vivo whole blood model, the plasma concentrations of matrix metallopeptidase 9 (MMP9, #DY911, R&D Systems, Minneapolis, USA), IL-6 (#555220, BD Biosciences, San Jose, USA), and IL-8 (#DY208, R&D Systems) were measured in citrate-anticoagulated plasma using enzyme-linked immunosorbent assay according to the respective manufacturer’s instructions.

    Techniques: Infection